AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 82 min read$PDEX

Biotech Stocks At 52-Week Highs - PDEX +18% On FY'26 Results, ODTX +8%, EOLS, BFRI, DRTS

Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.

Original reporting
rttnews.com
Published Sep 8, 2026, 2:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 3:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PDEX
Bullish
high confidence
Mentioned
$PDEX · $ODTX · $EOLS · $BFRI · $DRTS
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PDEXBullishMed
01

Why it matters

Earnings beats and trial updates drive short‑term price spikes, but underlying loss profiles and cash burn remain concerns.

02

Market read

Micro‑cap biotech earnings rally highlights sector momentum but underscores varied profitability.

03

What to watch

Potential regulatory or reimbursement risks for emerging therapies could curb upside.

Relevance 6/10Novelty 7/10Timing: Friday trade (Sept 4)

Background

The article aggregates FY2026 and Q2 results for five biotech companies, each hitting 52‑week highs after earnings releases.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Pro-Dex reported FY2026 net sales up 16% to $77.5M and profit of $13.7M, driving an 18% stock surge to a 52‑week high.

Expected impact

Potential continuation of rally if guidance remains positive.

Evidence & confidence

First‑report earnings with double‑digit profit growth for a micro‑cap biotech.

$ODTXBullishMedium confidence
Context

Odyssey Therapeutics posted Q2 net loss widening 28% to $52.8M and announced Phase 2b trial start, sending the stock up 8% to a 52‑week high.

Expected impact

Short‑term upside expected; long‑term depends on trial data.

Evidence & confidence

New trial news combined with earnings loss; mixed impact.

$EOLSBullishMedium confidence
Context

Evolus reported Q2 revenue up 21% to $84.1M and GAAP loss narrowing to $4.5M, lifting the stock 2% to a 52‑week high.

Expected impact

Likely modest upside as market digests earnings.

Evidence & confidence

First‑report earnings with solid top‑line growth for a small cap.

$BFRIBullishMedium confidence
Context

Biofrontera posted Q2 product revenue up 32.9% and loss reduced to $0.6M, pushing the stock 6% to a 52‑week high.

Expected impact

Potential short‑term rally; long‑term depends on product adoption.

Evidence & confidence

Earnings release with meaningful margin improvement for a niche biotech.

$DRTSNeutralLow confidence
Context

Alpha Tau reported Q2 net loss widening to $68.8M but announced progress on Alpha DaRT therapy, sending the stock to a 52‑week high.

Expected impact

Limited upside unless trial data materializes.

Evidence & confidence

Earnings loss dominates despite clinical news for a micro‑cap.

Market effects

Sector

Biotech sector shows broad earnings strength, supporting sector‑wide optimism.

Regional

U.S. small‑cap biotech market gains momentum.

Global

Limited to investors focused on U.S. biotech micro‑caps.

Counterpoint

What could challenge this read

High valuations may be unjustified given modest profit scales and ongoing losses.

Key entities

  • company
    Pro-Dex Inc.

    Medical device maker reporting profit growth.

  • company
    Odyssey Therapeutics Inc.

    Clinical‑stage biotech with new Phase 2b trial.

  • company
    Evolus Inc.

    Aesthetic injectables firm with revenue growth.

  • company
    Biofrontera Inc.

    Dermatology biotech improving margins.

  • company
    Alpha Tau Medical Ltd.

    Oncology firm advancing Alpha DaRT therapy.

Read at source← All news

Related articles

OCT 19
$DRTSHighAI 9/10

FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS) By FinanceWire

Alpha Tau Medical (NASDAQ: DRTS) received FDA approval to expand its U.S. brain cancer trial, doubling enrollment to 20 patients. The company will present updated REGAIN trial data on November 13, including new measures like progression-free survival and quality of life. Alpha DaRT technology aims to treat recurrent glioblastoma with localized radiation.

investing.com2 min
OCT 19
$DRTSMedAI 8/10

FDA expands Alpha Tau glioblastoma trial to 20 patients

Alpha Tau Medical (NASDAQ:DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma, increasing enrollment to 20 patients and adding new endpoints. The trial, presented at the Society for Neuro-Oncology Annual Meeting, evaluates the safety and feasibility of Alpha DaRT therapy. Alpha Tau's treatment is not yet approved for commercial use.

investing.com2 min
OCT 12
$ODTXMed

Odyssey Therapeutics to present phase 2a trial design for UC

Odyssey Therapeutics (NASDAQ:ODTX) will present a Phase 2a trial design for OD-001 combined with vedolizumab in ulcerative colitis at the American College of Gastroenterology 2026 Annual Scientific Meeting. The trial will enroll up to 146 patients globally, with topline results expected in the second half of 2027. The company aims to target both innate and adaptive immunity in the disease.

investing.com2 min
OCT 8
$ODTXMed

Raymond James initiates Odyssey Therapeutics stock coverage with outperform rating

Raymond James initiated coverage on Odyssey Therapeutics (ODTX) with an Outperform rating and a $42.00 price target. The stock is currently at $18.12, down 11% in the past week but up 10% year-to-date. The company is developing treatments for autoimmune and inflammatory conditions, with its lead asset OD-001 in Phase 2 trials. Analysts highlight the company's long-term potential and preclinical pipeline, though cash burn is noted.

investing.com2 min